PROSPECTIVE INVESTIGATION OF CLINICAL AND IMMUNOLOGICAL STATUS IN PATIENTS WITH NEWLY DIAGNOSED SARCOIDOSIS
https://doi.org/10.18093/0869-0189-2014-0-1-61-65
Abstract
Cytokine profile in bronchoalveolar lavage fluid (BALF) and blood serum was investigated in 80 patients with newly diagnosed sarcoidosis. Of them, 42 patients were treated with prednisolone and 38 patients were treated with fenspirid (Eurespal). BALF interleukin (IL) concentration was higher than serum IL concentration that could reflect a local immune response. To the 6th month of the therapy, significant blood levels of IL-2, IL-4 and IL-5 in prednisolone-treated patients were found compared to fenspirid-treated patients that could indicate an increased immune Tx-2 activity that, in turn, could facilitate development of prednisolone adverse effects. Treatment with fenspirid during 6 months has led to increased production of IL-10 that was 2.5-fold higher compared to IL-10 level in prednisolone-treated patients. The results suggest more effective inhibition of excessive immune inflammation in prednisolone-treated patients.
About the Authors
N. G. Dem'yanenko
ФГБУ "Центральный научно-исследовательский институт туберкулеза" РАМН: 107564, Москва, Яузская аллея, 2
Russian Federation
Russian Federation
V. V. Romanov
ФГБУ "Центральный научно-исследовательский институт туберкулеза" РАМН: 107564, Москва, Яузская аллея, 2
Russian Federation
Russian Federation
M. M. Averbakh
ФГБУ "Центральный научно-исследовательский институт туберкулеза" РАМН: 107564, Москва, Яузская аллея, 2
Russian Federation
Russian Federation
S. V. Lyamina
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И.Евдокимова" Минздрава России: 127473, Москва, ул. Делегатская, 20 / 1
Russian Federation
Russian Federation
I. Yu. Malyshev
ГБОУ ВПО "Московский государственный медико-стоматологический университет им. А.И.Евдокимова" Минздрава России: 127473, Москва, ул. Делегатская, 20 / 1
Russian Federation
Russian Federation
E. I. Shmelev
ФГБУ "Центральный научно-исследовательский институт туберкулеза" РАМН: 107564, Москва, Яузская аллея, 2
Russian Federation
Russian Federation
References
1. Чучалин А.Г. (ред.). Саркоидоз. М.: Атмосфера; 2010. 80–86.
2. Фрейдлин И.С., Тотолян А.А. Иммунопатологические механизмы воспаления бронхов и легких. В кн.: Федосеев Г.Б. (ред.). Механизмы воспаления бронхов и легких и противовоспалительная терапия. СПб: НормедИздат; 1998. 195–298.
3. Маянский Д.Н. Хроническое воспаление. М.: Медицина; 1991.
4. Hunninghake G.W., Crystal R.G. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N. Engl. J. Med. 1981; 305: 429–434.
5. Newman L.S., Rose G.S., Maler L.A. Sarcoidosis. N. Engl. J. Med. 1997, 336: 1224–1234.
6. Muller-Quernheim J. Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology. Sarcoidos. Vasc. Diffuse Lung Dis. 1998; 15: 22–37.
7. Keicho N., Kitamura K., Takaku F., Yotsumoto H.L. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 1990; 98:1125–1129.
8. Lawrence E.C., Brousseau K.P., Berger M.B. et al. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am. Rev. Respir. Dis. 1988, 137: 759–764.
Review
For citations:
Dem'yanenko N.G., Romanov V.V., Averbakh M.M., Lyamina S.V., Malyshev I.Yu., Shmelev E.I. PROSPECTIVE INVESTIGATION OF CLINICAL AND IMMUNOLOGICAL STATUS IN PATIENTS WITH NEWLY DIAGNOSED SARCOIDOSIS. PULMONOLOGIYA. 2014;(1):61-65. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-1-61-65
Views:
938
Email this article 